fluoxetine has been researched along with Anxiety, Separation in 10 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Anxiety, Separation: Anxiety experienced by an individual upon separation from a person or object of particular significance to the individual.
Excerpt | Relevance | Reference |
---|---|---|
"To assess the efficacy of fluoxetine for the long-term treatment of children and adolescents with anxiety disorders, including generalized anxiety disorder, separation anxiety disorder, and/or social phobia." | 9.11 | Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. ( Axelson, D; Birmaher, B; Brent, D; Bridge, J; Clark, DB; Ehmann, M; Kalas, C; Monk, K; Muthen, B; Wood, DS, 2005) |
"An open-label pilot study examined fluoxetine treatment in 16 outpatients (9-18 years old) with mixed anxiety disorders." | 9.08 | Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. ( Asche, BK; Dummit, ES; Fairbanks, JM; Kentgen, LM; Klein, RG; Martin, J; Pine, DS; Tancer, NK, 1997) |
"To assess the efficacy of fluoxetine for the long-term treatment of children and adolescents with anxiety disorders, including generalized anxiety disorder, separation anxiety disorder, and/or social phobia." | 5.11 | Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial. ( Axelson, D; Birmaher, B; Brent, D; Bridge, J; Clark, DB; Ehmann, M; Kalas, C; Monk, K; Muthen, B; Wood, DS, 2005) |
"An open-label pilot study examined fluoxetine treatment in 16 outpatients (9-18 years old) with mixed anxiety disorders." | 5.08 | Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. ( Asche, BK; Dummit, ES; Fairbanks, JM; Kentgen, LM; Klein, RG; Martin, J; Pine, DS; Tancer, NK, 1997) |
"Canine separation anxiety is a common behavioral problem presented to veterinarians." | 2.73 | Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety. ( Ciribassi, JJ; Clark, TP; Douglass, G; Horwitz, D; Houpt, KA; Kroll, TL; Landsberg, GM; Luescher, A; Moffat, KS; Reisner, IR; Robertson-Plouch, C; Simpson, BS; Veenhuizen, MF; Zimmerman, A, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (50.00) | 18.2507 |
2000's | 4 (40.00) | 29.6817 |
2010's | 1 (10.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Karagiannis, CI | 1 |
Burman, OH | 1 |
Mills, DS | 1 |
Clark, DB | 1 |
Birmaher, B | 1 |
Axelson, D | 1 |
Monk, K | 1 |
Kalas, C | 1 |
Ehmann, M | 1 |
Bridge, J | 1 |
Wood, DS | 1 |
Muthen, B | 1 |
Brent, D | 1 |
Bhansali, P | 1 |
Dunning, J | 1 |
Singer, SE | 1 |
David, L | 1 |
Schmauss, C | 1 |
Simpson, BS | 1 |
Landsberg, GM | 1 |
Reisner, IR | 1 |
Ciribassi, JJ | 1 |
Horwitz, D | 1 |
Houpt, KA | 1 |
Kroll, TL | 1 |
Luescher, A | 1 |
Moffat, KS | 1 |
Douglass, G | 1 |
Robertson-Plouch, C | 1 |
Veenhuizen, MF | 1 |
Zimmerman, A | 1 |
Clark, TP | 1 |
Campbell, M | 1 |
Cueva, JE | 1 |
Fairbanks, JM | 1 |
Pine, DS | 1 |
Tancer, NK | 1 |
Dummit, ES | 1 |
Kentgen, LM | 1 |
Martin, J | 1 |
Asche, BK | 1 |
Klein, RG | 1 |
Clarke, AS | 2 |
Kraemer, GW | 2 |
Kupfer, DJ | 1 |
Ebert, MH | 1 |
Schmidt, DE | 1 |
McKinney, WT | 1 |
Lee, HJ | 1 |
Kim, JW | 1 |
Yim, SV | 1 |
Kim, MJ | 1 |
Kim, SA | 1 |
Kim, YJ | 1 |
Kim, CJ | 1 |
Chung, JH | 1 |
Koizumi, H | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Vilazodone for Separation Anxiety Disorder[NCT01999920] | Phase 4 | 24 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
This standard scale will be used to assess severity of depression, looking at change in total score from baseline to week 12, rating severity of depression on a scale from 0 (least depression) to 50 (greatest depression). (NCT01999920)
Timeframe: Up to 12 weeks
Intervention | units on a scale (Mean) |
---|---|
Vilazodone | 3.7 |
Placebo | 8.4 |
Measure Description: (10 min) Quality of Life Enjoyment & Satisfaction Questionnaire (Q-LES-Q, Endicott et al, 1993): self-rated assessment of quality of life. 16 items related to life quality, each rated on a score of 1 (very poor) to 5 (very good), with a minimum total score of 16, and a maximum total score of 80. (NCT01999920)
Timeframe: Up to 12 weeks
Intervention | units on a scale (Mean) |
---|---|
Vilazodone | 68.9 |
Placebo | 47.8 |
Measure Description: (15 min) Adult Separation Anxiety - 27 Scale 27 items pertaining to adult separation anxiety, each self-rated on a four-point scale, 0=best, 3=worse. Minimum Total Score=0 (better); Maximum Total Score = 81 (worse) (NCT01999920)
Timeframe: Up to 12 weeks
Intervention | units on a scale (Mean) |
---|---|
Vilazodone | 14.4 |
Placebo | 40.6 |
The Structured Clinical Interview for Separation Anxiety Disorder was modified for DSM-5. The eight separation anxiety disorder criteria are rated for both childhood (rated at baseline only) and past week time frames, scored as 0 (not at all), 1 (sometimes), 2 (often) or ? (don't recall). In keeping with the DSM-5 guidelines, endorsement of three or more of the eight criterion symptoms (symptoms rated as '2' or 'often') is used as a threshold to determine categorical (yes/no) diagnosis of separation anxiety disorder. Scores on each of the eight items are also summed to produce a continuous measure of separation anxiety symptoms experienced during childhood and adulthood (range for each scale=0-16). (NCT01999920)
Timeframe: Baseline and week 12
Intervention | units on a scale (Mean) |
---|---|
Vilazodone | 3.1 |
Placebo | 5.0 |
"Clinical Global Impression-Improvement Scale rating at week 12 A quickly administered and widely used observer rating, with ratings from 1 (very much improved) to 7 (very much worse). Responder is a score of 1 or 2." (NCT01999920)
Timeframe: Up to 12 weeks
Intervention | Participants (Count of Participants) |
---|---|
Vilazodone | 7 |
Placebo | 4 |
Measure Description: (15 min) Attachment Style Questionnaire (Feeney at al., 1994) 40 items relating to quality of adult relationships. Questionnaire includes questions concerning Confidence (8 items, minimum score=8, maximum score=48), Discomfort (10 items, minimum score=10, maximum score=60), Relationships as Secondary (7 items, minimum score=7, maximum score=42), Need for Approval (7 items, minimum score=7, maximum score =42), and Preoccupation with Relationships (8 items, minimum score = 8, maximum score=48), each self-rated on a six-point scale, each self-rated from 1 (totally disagree) to 6 (totally agree). (NCT01999920)
Timeframe: Up to 12 weeks
Intervention | units on a scale (Mean) | ||||
---|---|---|---|---|---|
Confidence | Discomfort with Closeness | Relationships as Secondary | Need for Approval | Preoccupation with Relationships | |
Placebo | 26.9 | 42.3 | 20.7 | 23.6 | 32.1 |
Vilazodone | 32.3 | 35.6 | 16.3 | 20.6 | 30.0 |
1 review available for fluoxetine and Anxiety, Separation
Article | Year |
---|---|
Psychopharmacology in child and adolescent psychiatry: a review of the past seven years. Part II.
Topics: Adolescent; Alprazolam; Anticonvulsants; Antipsychotic Agents; Anxiety, Separation; Bipolar Disorder | 1995 |
4 trials available for fluoxetine and Anxiety, Separation
Article | Year |
---|---|
Dogs with separation-related problems show a "less pessimistic" cognitive bias during treatment with fluoxetine (Reconcileā¢) and a behaviour modification plan.
Topics: Administration, Oral; Animals; Anxiety, Separation; Behavior, Animal; Discrimination, Psychological; | 2015 |
Fluoxetine for the treatment of childhood anxiety disorders: open-label, long-term extension to a controlled trial.
Topics: Adolescent; Anxiety Disorders; Anxiety, Separation; Child; Female; Fluoxetine; Follow-Up Studies; Hu | 2005 |
Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety.
Topics: Administration, Oral; Animals; Antidepressive Agents, Second-Generation; Anxiety, Separation; Behavi | 2007 |
Open fluoxetine treatment of mixed anxiety disorders in children and adolescents.
Topics: Adolescent; Anti-Anxiety Agents; Anxiety Disorders; Anxiety, Separation; Child; Female; Fluoxetine; | 1997 |
5 other studies available for fluoxetine and Anxiety, Separation
Article | Year |
---|---|
Early life stress alters adult serotonin 2C receptor pre-mRNA editing and expression of the alpha subunit of the heterotrimeric G-protein G q.
Topics: Age Factors; Animals; Anxiety, Separation; Body Weight; Depressive Disorder; Emotions; Environment; | 2007 |
Effects of rearing condition on HPA axis response to fluoxetine and desipramine treatment over repeated social separations in young rhesus monkeys.
Topics: Adrenocorticotropic Hormone; Analysis of Variance; Animals; Antidepressive Agents; Anxiety, Separati | 1998 |
Biogenic amine activity in response to fluoxetine and desipramine in differentially reared rhesus monkeys.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animal Husbandry; Animals; Antidepressive Agents, Second-Generation; | 1999 |
Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety, Separation; Apoptosis; Cell Division; De | 2001 |
Fluoxetine and suicidal ideation.
Topics: Adolescent; Anxiety, Separation; Dose-Response Relationship, Drug; Fluoxetine; Humans; Male; Obsessi | 1991 |